Elanco Animal Health Incorporated (ELAN) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Greenfield, IN, United States. Le PDG actuel est Jeffrey N. Simmons.
ELAN a date d'introduction en bourse 2018-09-20, 9,000 employés à temps plein, cotée sur le NYSE, une capitalisation boursière de $11.99B.
Elanco Animal Health Incorporated is a global animal health company that innovates, develops, manufactures, and markets pharmaceutical and nutritional products for both companion animals and farm animals. For pets, the company offers disease prevention products such as parasiticides and vaccines under brands including Seresto, Advantage, and Advantix, as well as therapeutic treatments for pain, osteoarthritis, and dermatological conditions. In the farm animal sector, Elanco provides vaccines, antibiotics, parasiticides, and nutritional health products for poultry, aquaculture, ruminant, and swine production, with key brands including Rumensin and Baytril. The company distributes its products through veterinarians, third-party distributors, and direct relationships with farm animal producers. Founded in 1954 and headquartered in Greenfield, Indiana, Elanco serves a diverse customer base spanning veterinary clinics and agricultural operations worldwide.
